Literature DB >> 12429582

The isolated blood-perfused rat heart: an inappropriate model for the study of ischaemia- and infarction-related ventricular fibrillation.

Hugh Clements-Jewery1, David J Hearse, Michael J Curtis.   

Abstract

1. Well-characterized in vivo and in vitro models exist for the study of ischaemia- and infarction-related ventricular fibrillation (VF). In rats in vivo, VF appears to occur in distinct acute ischaemia- (early) and infarction-related (late) phases. Interestingly, isolated buffer-perfused rat hearts do not develop late VF. This raises the possibility that unidentified components of the blood may be responsible for late VF. We thus sought to characterize an isolated blood-perfused rat heart in order to investigate the possible influence of blood components on arrhythmias arising from ischaemia and infarction. 2. Hearts, excised from male Wistar rats, were perfused in the Langendorff mode with blood from support rats (male Wistar, 350-430 g) via an extracorporeal circuit. Perfused hearts underwent left coronary artery occlusion for 240 min or a sham procedure (n=10 group(-1)). 3. Only 10% of ischaemic hearts developed late VF (90-240 min). Tissue myeloperoxidase activity (an index of neutrophil accumulation) increased during ischaemia from 0.017+/-0.004 (six fresh hearts) to 0.056+/-0.005 units mg protein(-1) (P<0.05) at 240 min, but values were similar in sham hearts (0.083+/-0.013). Likewise, the decline (-1 vs 240 min of ischaemia shown) in circulating total white blood cells from 6.8+/-0.5 to 1.9+/-0.2 x 10(3) micro l(-1) and in platelets from 441+/-32 to 274+/-16 x 10(3) micro l(-1) (both P<0.05) was similar in time-matched sham hearts (data not shown). 4 Surprisingly, only 10% of ischaemic hearts developed early VF (0-90 min), although the incidence of early ventricular tachycardia was 100% in these hearts (P<0.05 vs sham hearts). Blood K+ values were normal (hyperkalaemia suppresses VF). 5 Although late VF was absent in blood-perfused hearts, it would be premature to conclude from this that late VF is not mediated by blood components. This is because the similar neutrophil accumulation in ischaemic and sham hearts, the decline in numbers of circulating blood components, and the unexpected paucity of early VF all question the validity of the model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12429582      PMCID: PMC1573593          DOI: 10.1038/sj.bjp.0704977

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  49 in total

Review 1.  Release of vasoactive substances during cardiopulmonary bypass.

Authors:  S W Downing; L H Edmunds
Journal:  Ann Thorac Surg       Date:  1992-12       Impact factor: 4.330

2.  Cardioprotection: intermittent ventricular fibrillation and rapid pacing can induce preconditioning in the blood-perfused rat heart.

Authors:  D J Hearse; R Ferrari; F J Sutherland
Journal:  J Mol Cell Cardiol       Date:  1999-11       Impact factor: 5.000

3.  Resuscitation fluids for the treatment of hemorrhagic shock in dogs: effects on myocardial blood flow and oxygen transport.

Authors:  A R Tait; L O Larson
Journal:  Crit Care Med       Date:  1991-12       Impact factor: 7.598

4.  Dichotomy in the post-ischemic metabolic and functional recovery profiles of isolated blood-versus buffer-perfused heart.

Authors:  M Galiñanes; P Bernocchi; V Argano; A Cargnoni; R Ferrari; D J Hearse
Journal:  J Mol Cell Cardiol       Date:  1996-03       Impact factor: 5.000

5.  Accumulation of polymorphonuclear leukocytes during 3-h experimental myocardial ischemia.

Authors:  R L Engler; M D Dahlgren; M A Peterson; A Dobbs; G W Schmid-Schönbein
Journal:  Am J Physiol       Date:  1986-07

6.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1989-08-10       Impact factor: 91.245

7.  A modified model of global ischaemia: application to the study of syncytial mechanisms of arrhythmogenesis.

Authors:  P D Ridley; M H Yacoub; M J Curtis
Journal:  Cardiovasc Res       Date:  1992-04       Impact factor: 10.787

8.  Quantification of arrhythmias using scoring systems: an examination of seven scores in an in vivo model of regional myocardial ischaemia.

Authors:  M J Curtis; M J Walker
Journal:  Cardiovasc Res       Date:  1988-09       Impact factor: 10.787

9.  Brief, intermediate and prolonged ischemia in the isolated crystalloid perfused rat heart: relationship between susceptibility to arrhythmias and degree of ultrastructural injury.

Authors:  T Ravingerova; N Tribulova; J Slezak; M J Curtis
Journal:  J Mol Cell Cardiol       Date:  1995-09       Impact factor: 5.000

10.  Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium.

Authors:  K M Mullane; R Kraemer; B Smith
Journal:  J Pharmacol Methods       Date:  1985-11
View more
  6 in total

1.  Unravelling mechanisms underlying ischaemic arrhythmias - the importance of models.

Authors:  L J Guppy; M J A Walker
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Antiarrhythmic drug research.

Authors:  M J A Walker
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Nupafant, a PAF-antagonist prototype for suppression of ventricular fibrillation without liability for QT prolongation?

Authors:  K E Baker; L M Wood; M Whittaker; M J Curtis
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

Review 4.  Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic antiarrhythmic drug development and for safety pharmacology evaluation.

Authors:  Hugh Clements-Jewery; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Complex adrenergic and inflammatory mechanisms contribute to phase 2 ventricular arrhythmias in anaesthetized rats.

Authors:  Hugh Clements-Jewery; Ellen Andrag; David J Hearse; Michael J Curtis
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

6.  Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass.

Authors:  Hugh Clements-Jewery; Fiona J Sutherland; Mary C Allen; W Ross Tracey; Metin Avkiran
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.